The acquisition of the FDA-approved facility is a strategic move for Eli Lilly, aiming to enhance its manufacturing capabilities and meet the growing demand for its injectable medicines. This expansion is likely to positively impact investor sentiment and the company's long-term growth prospects, given the emphasis on increasing production capacity and the facility's dedication to Lilly's manufacturing mission. The positive outlook is based on the strategic nature of the acquisition and its alignment with Lilly's growth and innovation goals.